Key result
Flecainide safely terminates and suppresses AF in patients without structural heart disease.
Why the study?
The use of flecainide for AF rhythm control is limited despite guideline recommendations and evidence of safety and efficacy in patients without structural heart disease.
Does flecainide improve the restoration and maintenance of normal sinus rhythm in patients with atrial fibrillation without structural heart disease?
Does flecainide improve the restoration and maintenance of normal sinus rhythm in patients with atrial fibrillation without structural heart disease?
Flecainide is a safe and effective first-line therapy for rhythm control in atrial fibrillation patients without structural heart disease, despite historical underutilization.
Answers are grounded in this paper and cite their sources.
May support flecainide for AF rhythm control without SHD; leaves open updated RCTs to address underutilization.
Atrial fibrillation (AF) is the most common sustained arrhythmia and is associated with substantial morbidity and impairment of quality of life. Restoration and maintenance of normal sinus rhythm is a desirable goal for many patients with AF; however, this strategy is limited by the relatively small number of antiarrhythmic drugs (AADs) available for AF rhythm control. Although it is recommended in current medical guidelines as first-line therapy for patients without structural heart disease, the use of flecainide has been curtailed since the completion of the Cardiac Arrhythmia Suppression Trial. In clinical trials and real-world use, flecainide has proven to be more effective than other AADs for the acute termination of recent onset AF. Flecainide is also moderately effective and, with the exception of amiodarone, equivalent to other AADs for the chronic suppression of paroxysmal and persistent AF. In patients without structural heart disease, flecainide has been demonstrated to be safe and well tolerated relative to other AADs. Despite this favorable profile, flecainide is underutilized, likely due to a perceived risk of ventricular proarrhythmia, a concern that has not been borne out in patients without underlying structural heart disease. Guidelines for administration and use of flecainide are summarized in this review.
No takes yet. Share an insight, caveat, or question.
Echt et al. (2020) conducted a review in Atrial fibrillation. Flecainide vs. Other antiarrhythmic drugs was evaluated. Flecainide is effective for the acute termination and chronic suppression of atrial fibrillation, and is safe and well-tolerated in patients without structural heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: